Orthofix Int'l (OFIX) Tops Q2 EPS by 5c, Beats on Revenues; Raises FY!& Sales Outlook Above Consensus

Orthofix Int'l (NASDAQ: OFIX) reported Q2 EPS of $0.42, $0.05 better than the analyst estimate of $0.37. Revenue for the quarter came in at $108.9 million versus the consensus estimate of $102.94 million.

Second Quarter Highlights

• Net sales of $108.9 million, an increase of 4.7% compared to prior year or 5.1% on a constant currency basis
• Biologics sales of $15.7 million, an increase of 9.9% compared to prior year
• Spine Fixation sales of $21.4 million, an increase of 17.1% compared to prior year

GUIDANCE:

Orthofix Int'l sees FY2017 revenue of $422-425 million, versus the consensus of $414.14 million.

For earnings history and earnings-related data on Orthofix Int'l (OFIX) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c